跳至主要内容
临床试验/CTRI/2023/06/053981
CTRI/2023/06/053981尚未招募Unknown

A single centre prospective observational study to compare the outcomes & toxicities of Azacitidine plus Venetoclax (AZA plus VEN) with 3 plus 7 induction chemotherapy (IC) with Cytarabine and Daunorubicin in patients with Acute Myeloid Leukemia (AML)

Dr Manju Sengar0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
Unknown
状态
尚未招募
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

入选标准

  • 1- Newly diagnosed patients with Acute Myeloid Leukemia (AML) of any risk group, 18 years of age or older
  • 2- No prior therapy
  • 3- Willing to continue treatment (induction) at TMH

排除标准

  • 1- Acute Promyelocytic Leukemia
  • 2- Patients not willing to participate in the study

研究者

发起方
Dr Manju Sengar

相似试验